Posted by Michael Wonder on 19 Jan 2023
NICE backs Alnylam’s Amvuttra for rare form of amyloidosis
19 January 2023 - Alnylam’s gene-silencing drug Amvuttra has been recommended as a treatment for hereditary transthyretin-related amyloidosis by NICE, paving the way for the drug to be made available on the NHS in England and Wales.
Amvuttra (vutrisiran) is a follow-up to Alnylam’s earlier RNA interference ATTR amyloidosis therapy Onpattro (patisiran), which was cleared by NICE for NHS use in 2019, but offers a simpler, more patient friendly dosing regimen.
